黒田 啓史 くろだ ひろし 先生

来歴等

略歴

1982年 京都府立医科大学 卒業
1982年 京都府立医科大学附属病院 研修医
1984年 国立舞鶴病院 小児科 医員
1986年 京都府立医科大学附属病院 修練医
1987年 国保能登川病院 小児科 医員
1987年 京都府立医科大学 研修員（小児科学教室）
1989年 第一岡本病院 小児科 医員
1990年 福井愛育病院 小児科 部長
1992年 京都府立医科大学 研修員（小児科学教室）修了
1994年 米国フィラデルフィア小児病院 研究員
1996年 宮崎医科大学 文部教官兼任講師（小児科学教室）
2000年 宮崎医科大学 文部教官講師（小児科学教室）
2001年 京都市立病院 小児科 部長
2015年 京都市立病院 副院長
2020年 京都市立病院 院長 管理者就任

論文

• 1 Differential susceptibility of HLA class II antigens induced by γ-interferon in human neuroblastoma cell lines．Cancer Res. 49：1824?1828, 1989

  Sugimoto T., Horii Y., Hino T., Kemshead J.T., Kuroda H., Sawada T., Morioka H. Imanishi J. and Inoko H.

• 2 Different drug sensitivity in two neuroblastoma cell lines established from the same patient before and after chemotherapy．International Journal of Cancer, 47：732?737, 1991

  Kuroda H., Sugimoto T., Ueda K., Tsuchida S., Horii Y., Inazawa J., Sato K. and Sawada T.

• 3 Long-term effects of mass screening for neuroblastoma in infancy．Am．J．Pediatr．Hemato1．0ncol. 13：3?7，1991

  Sawada T., Matsumura T., Kawakatsu H., Sugimoto T., Kuroda H., Hosoi H., Michihata T., Saida T. and Hino T.

• 4 Physical mapping of the DDX1 gene to 340 kb 5' of MYCN. Oncogene. 13: 1561-1565，1996

  Kuroda H., White P.S., Sulman E.P., Manohar C.F., Reiter J.L., Cohn S.L. and Brodeur G.M.

• 5 Frequent detection of TrkA expression in human neuroblastoma cell lines. Acta Paediatrica Japonica. 40 : 644-646, 1998

  Horii Y., Kuroda H., and Sugimoto T.

• 6 Signal transduciotn pathway of TRK-B in human neuroblastoma cells. Jap. J. Cancer Res. 2001, 92: 152-160, 2001

  Sugimoto T., Kuroda H., Moritake H., Hattori S., and Horii Y.

• 7 Signaling pathway of ciliary neurotrophic factor in neuroblastoma cell lines. Med. Pediatr. Oncol. 36:118-121, 2001

  Kuroda H., Sugimoto T., Horii Y., and Sawada T.

• 8 Analysis of PTEN/MMAC1 alteration in neuroblastoma. Cancer Gen. Cytogen., 125: 151-155, 2001

  Moritake H, Horii Y, Kuroda H and Sugimoto T.

• 9 Outocome of acute lymphoblastic leukemia in children with AL90 regimen: Impact of rresponse to treatment and sex difference on prognostic factors. Med. Ped. Oncology, 37:10-19, 2001

  Ishii E, Eguchi H, Matsuzaki A, Koga H, Yanai F, Kuroda H, Kawakami K, Ayukawa H, Akiyoshi K, Kamizono J, Tamai Y, Kinukawa N and Okamura J.

• 10 Newly established clear cell sarcoma (malignant melanoma of soft parts) cell line expressing melanoma-associated Melan-A antigen and overexpressing C-MYC oncogene. Cancer Genet and Cytogenet, 135: 48-56, 2002

  Moritake H., Sugimoto T., Asada Y., Yoshida M., Maehara Y., Epstein A. L. and Kuroda H.

• 11 Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease. Bone Marrow Transplantation, December 1-2, 2003

  Imashuku S., Teramura T., Morimoto A., Naya M. and Kuroda H.

• 12 Non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from a family donor based on fetomaternal microchimerism in pediatric hematologic malignancies. J Pediatr Hematol Oncol., 26: 68-71, 2004

  Ishida H., Morimoto A., Yoshihara T., Kuroda H., Mori K., Fujii N., Tamura S., Hibi S., Todo S., Maruya E. and Imashuku S.

• 13 Treatment of Epstein-Barr virus-associated peripheral T-cell lymphoma. British Journal of Dermatology, 150:1038-1040, 2004

  Imashuku S., Teramura T., Konishi K., Kikuchi S., Tamura S., Maeda Y. and Kuroda H.

• 14 Non-T-cell-depleted HLA haploidentical stem cell transplantation based on feto-maternal microchimerism in pediatric patients with advanced malignancies. Bone Marrow Transplant, 34: 373-375, 2004

  Yoshihara T., Morimoto A., Inukai T., Kuroda H., Ishida H., Sugita K., Goi K., Imamura T., Todo S., Maruya E., Saji H., Nakazawa S. and Imashuku S.

• 15 Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo. Clin Cancer Res, 10:5940-5948, 2004

  Kuwahara Y., Hosoi H., Osone S., Kita M., Iehara T., Kuroda H. and Sugimoto T.

• 16 Establishment of a cell line from a malignant rhabdoid tumor of the liver lacking the function of two tumor suppressor genes, hSNF5/INI1 and p16. Cancer Genetics and Cytogenetics, 158:172-179, 2005

  Kuroda H., Moritake H., Sawada K., Kuwahara Y., Imoto I., Inazawa J. and Sugimoto T.

• 17 Successful non-T-cell-depleted HLA-haploidentical 3-loci mismatched bone marrow transplantation. Eur J Haematol, 74:529-532, 2005

  Yagyu S., Kuroda H., Fujiki A., Tamura S., Iehara T., Morimoto A., Sugimoto T., Imashuku S.

• 18 Response to imatinib mesylate in a patient with cyclic eosinophil oscillations. Int J Hematology, 81:310-314, 2005

  Imashuku S., Kakazu N., Ueda I., Morimoto A., Harada H., Teramura T., Fukushima-Nakase Y., Kuroda H.

• 19 Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction. J Clin Oncol 23: 5205-5210, 2005

  Gotoh T., Hosoi H., Iehara T., Kuwahara Y., Osone S., Tsuchiya K., Ohira M., Nakagawara A., Kuroda H. and Sugimoto T.

• 20 Infliximab for Pediatric Patients with Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. Jpn J Pediatric Hematol, 20:16-21, 2006

  Tamura S., Kuroda H., Maeda Y., Yagyu S., Nakai N., Ishida H., Yoshihara T., Morimoto A., Imashuku S.

• 21 Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents. Int J Hematology, 85:246-255, 2007

  Yoshihara T., Okada K., Kobayashi M., Kikuta A., Kato K., Adachi N., Kikuchi K., Ishida H., Hirota Y., Kuroda H., Nagatoshi Y., Inukai T., Koike K., Kigasawa H., Yagasaki H., Tokuda K., Kishimoto T., Nakano T., Fujita N., Goto H., Nakazawa Y., Kanegane H., Matsuzaki A., Osugi Y., Hasegawa D., Uoshima N., Nakamura K., Tsuchida M., Tanaka R., Watanabe A. and Yabe H.

• 22 Sensorineural hearing loss in a case of familiar hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer, 49(6):856-858, 2007

  Imashuku S., Kohdera U., Teramura T., Ueda I., Morimoto A., Naya M., Kuroda H.

• 23 Late appearance of a Philadelphia chromosome in a patient with therapy-related acute myeloid leukemia and high expression of EVI1. Cancer Genetics and Cytogenetics 180: 115-120, 2008

  Yagyu S., Morimoto A., Kakazu N., Tamura S., Fujiki A., Nakase Y., Iehara T., Hosoi H., and Kuroda H.

• 24 Trastuzumab activates allogeneic or autologous antibody-dependent cellular Cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the Cytotoxicity. Clin Cancer Res 14(4): 1192-1199, 2008

  Katsumi Y., Kuwahara Y., Tamura S., Kikuchi K., Otabe O., Tsuchiya K., Iehara T., Kuroda H., Hosoi H. and Sugimoto T.

• 25 Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am. J. Hematol. 83:721-727, 2008

  Sato E., Ohga S., Kuroda H., Yoshiba F., Nishimura M., Nagasawa M., Inoue M. and Kawa K.

• 26 Preoperative analysis of 11q loss using circulating tumor-released DNA in serum: A novel diagnostic tool for therapy stratification of neuroblastoma. Cancer Letters 309: 185-189, 2011

  Yagyu S., Iehara T., Gotoh T., Miyachi M., Katsumi Y., Kikuchi K., Tsuchiya K., Osone S., Kuroda H., Sugimoto T., Sawada T. and Hosoi H.

• 27 Allo-SCT in a patient with CRMCC with aplastic anemia using a reduced intensity conditioning regimen. Bone Marrow Transplant. 47(8): 1126-1127, 2012

  Asai D., Osone S., Imamura T., Sakaguchi H., Nishio N., Kuroda H., Kojima S., Hosoi H.

• 28 Stem cell transplantation for paediatric patients with non-anaplastic peripheral T-cell lymphoma in Japan.Br J Haematol. 159(1):88-93, 2012

  Kobayashi R., Fujita N., Mitsui T., Iwasaki F., Suzumiya J., Kuroda H., Nishimura R., Sasahara Y., Takeshita Y., Kato K., Okumura H., Sakamaki H., Yabe H., Kawa K., Kato K., Suzuki R.

• 29 A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines. Cancer Lett. 30;331(1):115-121, 2013

  Sugimoto T., Gotoh T., Yagyu S., Kuroda H., Iehara T., Hosoi H., Ohta S., Ohira M., Nakagawara A.

• 30 Case reports of severe congenital neutropenia treated with unrelated cord blood transplantation with reduced-intensity conditioning. J Pediatr Hematol Oncol, 38(1): 49-52, 2016.

  Osone S., Imamura T., Fukushima-Nakase Y., Kitamura-Masaki A., Kanai S., Imai T., Imashuku S., Kuroda H.

• 31 Allogeneic Hematopoietic Cell Transplantation for Dyskeratosis Congenita: A Report of 3 Cases. J Pediatr Hematol Oncol, 22: 2017.

  Tamura S, Imamura T, Urata T, Kobayashi M, Gen M, Tomii T, Do J, Osone S, Ishida H, Hosoi H, Kuroda H.

受賞

• 2001年 小児がん研究奨励賞